The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.

Authors :: van der Meel R
Symons MH
Kudernatsch R
Kok RJ
Schiffelers RM
Storm G
Gallagher WM
Byrne AT
Source :: Drug discovery today [Drug Discov Today] 2011 Mar; Vol. 16 (5-6), pp. 219-28. Date of Electronic Publication: 2011 Jan 22.
Publication Year :: 2011
Abstract: It has become increasingly apparent that current antiangiogenic therapy elicits modest effects in clinical settings. In addition, it remains challenging to treat cancer metastasis through antiangiogenic regimes. Rho GTPases are essential for vascular endothelial growth factor (VEGF)-mediated angiogenesis and are involved in tumour cell invasion. This review discusses novel therapeutic strategies that interfere with Rho GTPase signalling and further explores this network as a target for anticancer therapy through interference with tumour angiogenesis and invasion. Recent findings describe the development of innovative Rho GTPase inhibitors. Positive clinical effects of Rho GTPase targeting in combination with conventional anticancer therapy is of increasing interest.<br /> (Copyright © 2011. Published by Elsevier Ltd.)

Subjects :: Animals
Antineoplastic Agents pharmacology
Humans
Neoplasm Invasiveness
Neoplasm Metastasis
Neoplasms blood supply
Neoplasms pathology
Neovascularization, Pathologic drug therapy
Signal Transduction drug effects
Vascular Endothelial Growth Factor A metabolism
rho GTP-Binding Proteins antagonists & inhibitors
rho GTP-Binding Proteins metabolism
Angiogenesis Inhibitors pharmacology
Drug Delivery Systems
Neoplasms drug therapy

Full Text Access

Tools